Peroxisome Proliferator-Activated Receptor-α and Receptor-γ Activators Prevent Cardiac Fibrosis in Mineralocorticoid-Dependent Hypertension

Hypertension - Tập 42 Số 4 - Trang 737-743 - 2003
Marc Iglarz1, Rhian M. Touyz2, Émilie C. Viel3, Pierre Paradis4, Farhad Amiri5, Quy N. Diep6, Ernesto L. Schiffrin7
1Marc Iglarz From CIHR Multidisciplinary Research Group on Hypertension, Clinical Research Institute of Montreal, University of Montreal, Montreal, Quebec, Canada.
2Rhian M. Touyz From CIHR Multidisciplinary Research Group on Hypertension, Clinical Research Institute of Montreal, University of Montreal, Montreal, Quebec, Canada.
3Emilie C. Viel From CIHR Multidisciplinary Research Group on Hypertension, Clinical Research Institute of Montreal, University of Montreal, Montreal, Quebec, Canada.
4Pierre Paradis From CIHR Multidisciplinary Research Group on Hypertension, Clinical Research Institute of Montreal, University of Montreal, Montreal, Quebec, Canada.
5Farhad Amiri From CIHR Multidisciplinary Research Group on Hypertension, Clinical Research Institute of Montreal, University of Montreal, Montreal, Quebec, Canada.
6Quy N. Diep From CIHR Multidisciplinary Research Group on Hypertension, Clinical Research Institute of Montreal, University of Montreal, Montreal, Quebec, Canada.
7Ernesto L. Schiffrin From CIHR Multidisciplinary Research Group on Hypertension, Clinical Research Institute of Montreal, University of Montreal, Montreal, Quebec, Canada.

Tóm tắt

Peroxisome proliferator-activated receptor (PPAR) activation may prevent cardiac hypertrophy and inhibit production of endothelin-1 (ET-1), a hypertrophic agent. The aim of this in vivo study was to investigate the effects of PPAR activators on cardiac remodeling in DOCA-salt rats, a model overexpressing ET-1. Unilaterally nephrectomized 16-week-old Sprague-Dawley rats (Uni-Nx) were randomly divided into 4 groups: control rats, DOCA-salt, DOCA-salt+rosiglitazone (PPAR-γ activator, 5 mg/kg per day), and DOCA-salt+fenofibrate (PPAR-α activator, 100 mg/kg per day). After 3 weeks of treatment, mean arterial blood pressure was significantly increased in DOCA-salt by 36 mm Hg. Mean arterial blood pressure was normalized by coadministration of rosiglitazone but not by fenofibrate. Both PPAR activators prevented cardiac fibrosis and abrogated the increase in prepro–ET-1 mRNA content in the left ventricle of DOCA-salt rats. Coadministration of rosiglitazone or fenofibrate failed to prevent thickening of left ventricle (LV) walls as measured by echocardiography and the increase in atrial natriuretic peptide mRNA levels. However, rosiglitazone and fenofibrate prevented the decrease in LV internal diameter and thus concentric remodeling of the LV found in DOCA-salt rats. Taken together, these data indicate a modulatory role of PPAR activators on cardiac remodeling in mineralocorticoid-induced hypertension, in part associated with decreased ET-1 production.

Từ khóa


Tài liệu tham khảo

Braunwald E Zipes DP Libby P. Heart Disease: A Textbook of Cardiovascular Medicine. 6th ed. Philadelphia Pa: WB Saunders Co; 2001: 503–534.

10.1016/S0022-2828(95)91263-0

10.1161/circ.103.2.319

10.1074/jbc.271.6.3221

10.1172/JCI116579

10.1093/cvr/27.12.2130

10.1161/hyp.39.2.679

10.1161/circ.96.6.1976

10.1161/01.res.0000060700.55247.7c

10.1161/circ.105.10.1240

10.1038/34178

10.1161/res.83.11.1097

10.1161/01.cir.0000039346.31538.2c

10.1073/pnas.91.23.11012

10.1172/JCI9056

10.1161/01.cir.0000016049.86468.23

10.1161/01.hyp.0000037969.41360.cc

10.1161/res.85.5.394

10.1002/jps.2600620215

10.1152/ajpheart.1999.277.5.H1967

10.1161/circ.69.4.6697466

10.1161/01.atv.0000047447.67827.cd

10.1016/0049-3848(95)00034-8

10.1038/sj.bjp.0704539

10.1016/0006-291X(89)92270-5

10.1074/jbc.M105490200

10.1161/01.atv.0000054195.35121.5e

10.1074/jbc.M000248200

10.1074/jbc.M202008200

10.1161/01.cir.0000038703.78148.54

10.1161/01.hyp.10.6.595

10.1080/ann.34.3.217.224

10.1291/hypres.20.263

Zicha J, Kunes J, Jelinek J. Age-dependent DOCA-salt hypertension in Brattleboro rats: the role of vasopressin. Physiol Bohemoslov. 1987; 36: 33–42.

10.1016/S0014-2999(99)00775-X

10.1042/CS103S284S

10.1042/CS103S016S

Thông tin
Thông tin xuất bản

Hypertension

Tập 42 Số 4

737-743

Thông tin tác giả